What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

November 27, 2022

Chad Pettit, the executive director of marketing and global biosimilars commercial lead at Amgen, discusses the most recent version of Amgen's Biosimilar Trends Report and what the report says about the current biosimilar market and how it could develop in the years to come.

VOLTAIRE-X Findings in Patients With Chronic Plaque Psoriasis Supported Interchangeability
The Top 5 Biosimilar Articles for the Week of November 21
Alvotech Snags Australian Approval for Adalimumab Biosimilar
Rezvoglar Becomes Second Interchangeable Insulin Biosimilar